Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers

Trial Profile

Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs ZW 25 (Primary)
  • Indications Cancer; Gastric cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Zymeworks
  • Most Recent Events

    • 12 Sep 2017 Results (n=16) presented at the 42nd European Society for Medical Oncology Congress
    • 11 Sep 2017 According to a Zymeworks media release, The dose escalation portion of the study enrolled patients with HER2-expressing cancers (either HER2 IHC 1+, 2+ or 3+, or FISH-positive) whose cancer had progressed after treatment with all therapies known to confer clinical benefit.
    • 11 Sep 2017 Results published in a Zymeworks Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top